• Home
  • About
  • Employers by Category
    • Agriculture
    • Automation
    • Cancer Research
    • Cloud Software
    • Contract Research
    • Diagnostics
    • Drug Discovery
    • Genetic Testing
    • Genomics
    • Healthcare Services
    • Human Longevity
    • Medical Devices
    • Medical Imaging
    • Other
    • Pharmaceuticals
    • Research Institutes
    • Software Development
    • Synthetic Biology
  • Educational Programs
    • Undergraduate Computational Biology/Bioinformatics Programs
    • Undergraduate Biostatistics Programs
    • Summer Programs for Undergrads
    • Graduate Computational Biology/Bioinformatics Programs
    • Graduate Biostatistics Programs
  • Our Department
Main Menu
  • Home
  • About
  • Employers by Category
    • Agriculture
    • Automation
    • Cancer Research
    • Cloud Software
    • Contract Research
    • Diagnostics
    • Drug Discovery
    • Genetic Testing
    • Genomics
    • Healthcare Services
    • Human Longevity
    • Medical Devices
    • Medical Imaging
    • Other
    • Pharmaceuticals
    • Research Institutes
    • Software Development
    • Synthetic Biology
  • Educational Programs
    • Undergraduate Computational Biology/Bioinformatics Programs
    • Undergraduate Biostatistics Programs
    • Summer Programs for Undergrads
    • Graduate Computational Biology/Bioinformatics Programs
    • Graduate Biostatistics Programs
  • Our Department

Intellia Therapeutics

40 Erie Street
Cambridge, MA 02139
Healthcare Services, Synthetic Biology
40 Erie Street
Cambridge, MA 02139
www.intelliatx.com

Description

Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help.

Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic.

Source: https://www.linkedin.com/company/intellia-therapeutics-inc-/

Company Size: 51-200 employees

Connect

  • Twitter URL
  • LinkedIn URL

Contact Us

CMU Computational Biology Department
5000 Forbes Ave
Pittsburgh, PA 15213
(412) 268-4671
social@cbd.cmu.edu

Legal Info

Follow our Twitter list of companies!

My Tweets

Computational Biology Career Events

No upcoming events

Copyright © 2018 Carnegie Mellon University. All Rights Reserved

Login

Lost your password?